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ABSTRACT
Gliomas are the most commonly diagnosed primary tumors of the central nervous 
system (CNS). Median times of survival are dismal regardless of the treatment 
approach, underlying the need to develop more effective therapies. Modulation of 
the immune system is a promising strategy as innate and adaptive immunity play 
important roles in cancer progression. Glioma associated microglia and macrophages 
(GAMs) can comprise over 30% of the cells in glioma biopsies. Gliomas secrete 
cytokines that suppress the anti-tumorigenic properties of GAMs, causing them to 
secrete factors that support the tumor’s spread and growth. Neuropilin 1 (Nrp1) 
is a transmembrane receptor that in mice both amplifies pro-angiogenic signaling 
in the tumor microenvironment and affects behavior of innate immune cells. Using 
a Cre-lox system, we generated mice that lack expression of Nrp1 in GAMs. We 
demonstrate, using an in vivo orthotopic glioma model, that tumors in mice with 
Nrp1-deficient GAMs exhibit less vascularity, grow at a slower pace, and are populated 
by increased numbers of anti-tumorigenic GAMs. Moreover, glioma survival times in 
mice with Nrp1-deficient GAMs were significantly longer. Treating wild-type mice 
with a small molecule inhibitor of Nrp1’s b1 domain, EG00229, which we show here 
is selective for Nrp1 over Nrp2, yielded an identical outcome. Nrp1-deficient or 
EG00229-treated wild-type microglia exhibited a shift towards anti-tumorigenicity 
as evident by altered inflammatory marker profiles in vivo and decreased SMAD2/3 
activation when conditioned in the presence of glioma-derived factors. These results 
provide support for the proposal that pharmacological inhibition of Nrp1 constitutes 
a potential strategy for suppressing glioma progression.
INTRODUCTION
Gliomas, the most common primary malignancies 
of the central nervous system (CNS), are diagnosed at 
a rate of 17,000 new cases per year in the United States 
[1]. Median time of survival after diagnosis, regardless 
of clinical management strategy, is dismal, averaging 
between 12 to 15 months [2]. Current treatment modalities 
consist of concomitant radio- and chemotherapy but are 
suboptimal in slowing disease progression. Patients 
incur frequent complications including seizures, 
fluctuating neurological symptoms, and adverse effects of 
chemotherapy. Thus, there is a substantial need to identify 
more effective and specific pharmacological targets for 
treatment. Apart from cytotoxic and anti-angiogenic 
therapies, modulation of the immune system is a promising 
strategy, as innate and adaptive immunity are implicated in 
playing important roles in cancer progression [3]. 
Neuropilin 1 (Nrp1), a cell-surface transmembrane 
receptor that functions as a co-receptor for several 
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signaling pathways, has received significant attention as 
a potential therapeutic target in glioma as well as in other 
cancer subtypes. Increased Nrp1 expression in glioma 
biopsies, specifically in glioma tumor cells, correlates 
with increased malignancy [4], whereas reducing Nrp1 
expression in glioma cells suppresses migration [5], 
proliferation and survival in vitro, and stem cell viability 
and tumor growth in vivo [6, 7].
Nrp1 has also been shown to function as a co-
receptor for VEGF-R on macrophages in the periphery 
in mouse tumor models, where it plays a key role in the 
accumulation of immunosuppressive and pro-angiogenic 
macrophages at sites of tumor hypoxia in pancreatic 
adenocarcinoma, breast cancer, and lung carcinoma, [8]. 
Microglia, the resident macrophages of the CNS, 
can comprise over 30% of the cells in glioma biopsies [9]. 
Gliomas are known to secrete cytokines that suppress the 
anti-tumorigenicity of microglia and other macrophages, 
causing them in turn to secrete factors that support tumor 
growth and spread [10]. However, it is also known that 
these glioma-associated microglia and macrophages 
(GAMs) can undergo an anti-tumorigenic shift depending 
on the microenvironment and the cytokines they are 
exposed to [11, 12]. Gliomas have been shown to express 
high levels of TGF-β, VEGFA, HGF, and Sema3a, which 
promote tumor growth [13], neo-vascularization [14], 
invasiveness [15], and dispersal [16]. Important to how 
the receptors for these cytokines conduct signaling is 
their co-receptor Neuropilin 1 (Nrp1), which amplifies the 
activation of their downstream effector pathways [17-22]. 
These receptors are expressed by macrophages as well 
[23, 24] and likely have an effect on their activity within 
tumor micro-environments enriched in their ligands.
Our group has shown that Nrp1 plays an important 
role in microglial activation and polarization [25]. More 
specifically, we have shown [25] that pro-tumorigenic 
M2 polarization of microglia can be blocked by a small 
molecule inhibitor of Nrp1’s b1 domain, EG00229 [26]. 
The b1 domain binds and amplifies signaling through the 
VEGF-A and TGFβ pathways ([26, 27]). Based on the 
above information, our group hypothesized that genetic 
ablation of Nrp1 from microglia and macrophages 
populating the glioma microenvironment would lead to 
a decrease in the capacity of the microenvironment to 
promote their pro-tumorigenic polarization and thus result 
in reduced tumor growth.
We demonstrate here using a syngeneic glioma 
model that tumors develop more slowly in mice in which 
Nrp1 has been genetically ablated from their microglia 
and macrophages. This decrease in tumor growth is 
correlated with an increase in GAM density, decreased 
neovascularization, and increased anti-tumorigenic 
polarization of the GAMs populating the tumors. In line 
with these findings, we find similar disease outcomes in 
mice administered an inhibitor of Nrp1’s b1 domain. Our 
findings support the proposal that targeting Nrp1 may be 
a promising therapeutic strategy for malignant glioma 
through the promotion of anti-tumorigenic polarization 
of GAMs, in addition to suppressing Nrp1’s previously 
characterized roles in amplifying angiogenic and 
proliferative signaling in endothelial and glioma-derived 
cancer cells, respectively.
RESULTS
Glioma associated microglia and macrophages 
express Nrp1
A critical factor in the progression of gliomas is 
their interaction with the surrounding tissue and cells. 
The tumor microenvironment directs and modulates the 
growth and metastatic propensity of glioma cells [34]. 
It has been shown that Nrp1 expression by tumor cells 
is correlated with the degree of biologic aggression of 
human gliomas [4, 20] but it is not known whether Nrp1 
is also expressed by macrophages within the human tumor 
microenvironment. We thus investigated whether glioma-
associated microglia and macrophages (GAMs) express 
Nrp1 using human tumor biopsies. Nrp1 expression was 
detected by immunofluorescence in Iba1-positive GAMs 
in glioma biopsies of varying grades (Figure 1). 
Glioma growth is impaired in mice with Nrp1-
deficient microglia/macrophages and mice 
treated with a pharmacological inhibitor of Nrp1, 
EG00229
Since genetic depletion of Nrp1 from tumor-
associated macrophages has been reported to decrease 
tumor growth in the periphery for pancreatic and lung 
tumor xenografts in mice [8], we next investigated whether 
CNS glioma tumor burden is different in wild type (wt) 
mice compared to mice with Nrp1-deficient microglia and 
macrophages. We generated mice that constitutively lack 
Nrp1 expression in microglia and macrophages (Nrp1MgKO) 
by crossing mice with lox-p sites flanking exon 2 of the 
Nrp1 gene (Nrp1fl/fl) to mice expressing Cre recombinase 
under the Csf1R promoter [30, 31]. For the disease model, 
we used the GL261 glioma cell line, which was derived 
from a chemically-induced C57BL/6 murine astrocytoma 
[28] and bears mutations in the tumor suppressor p53 and 
the oncogene KRas [35]. We previously stably-transfected 
this cell line with eGFP, generating GL261-eGFP, which 
was characterized in culture and in an in vivo glioma 
model [29]. Nrp1 mRNA expression was detected in the 
GL261-eGFP cell line and in wt microglia using primers 
designed to amplify a region of exon 2 that is excised by 
Cre recombination, but undetectable in Nrp1MgKO microglia 
(Supplementary Figure 1). Additionally, Csf1R expression 
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Figure 1: Expression of Nrp1 by glioma-associated microglia/macrophages in human tumor biopsies. Representative 
images of biopsies from patients diagnosed with a pilocytic astrocytoma (grade I), grade II glioma, grade III glioma, and grade IV 
glioblastoma multiforme (from left to right), which were stained for the microglial/macrophage marker Iba1 (red), Nrp1 (green), and DAPI 
(Blue). White bars, 50μm. 
Figure 2: Mice lacking Nrp1 in microglia/macrophages and mice treated with an Nrp1 inhibitor exhibit impaired 
glioma growth. A. Representative images of the GL261-eGFP- gliomas and CD31+ tumor vasculature in wild-type (wt) mice (top), 
Nrp1MgKO mice (middle), and wt mice administered the Nrp1 inhibitor EG00229 (75µM) via mini-osmotic pump/cannula (bottom) at 15 
days post-glioma induction (PGI). B. Representative staining of Csf1R in tumors from wt and Nrp1MgKO mice. C. Representative staining of 
Nrp1 by F4/80+ GAMs in wt and Nrp1MgKO mice. D. Quantification of tumor areas, and E. quantification of vessel luminal areas bordered 
by CD31+ staining in gliomas in wt, Nrp1MgKO, and EG00229-treated mice at 15 and 20 days PGI. Mice were administered EG00229 either 
throughout the disease course or after day 8 (D8, **= p < 0.01, ****= p < 0.0001). F. Survival curve post-glioma induction in wt and 
Nrp1MgKO mice. Two Nrp1MgKO mice survived to day 50, at which point the experiment was terminated (WT: n = 9, KO: n = 9).
Oncotarget9804www.impactjournals.com/oncotarget
relative to Iba1 expression, in the CNS of wild type and 
Nrp1MgKO mice remained unchanged (Supplementary 
Figure 1)
Gliomas were introduced into wt and Nrp1MgKO mice 
and allowed to engraft and develop. At 15 and 20 days 
after tumor initiation, tumor volumes were significantly 
lower in the Nrp1MgKO mice (Figure 2A, left column; 
D). Blood vessel density was visualized using an anti-
CD31 antibody and vessel luminal areas summated and 
quantified from random points throughout the tumors. 
Gliomas in Nrp1MgKO were found to have significantly 
decreased blood vessel luminal area relative to tumors 
in wt mice (Figure 2A middle and right columns, E). 
Additionally, tumor tissue from both genotypes was 
populated by prominent numbers of Csf1R expressing 
cells (Figure 2B). F4/80 GAMs in tumor tissue of wt mice 
stained positive for Nrp1 expression, while Nrp1 was not 
detectable in GAMs of Nrp1MgKO mice (Figure 2C).
To examine whether Nrp1 deficiency in GAMs 
had an effect on survival time, tumors were allowed to 
engraft in wt and Nrp1MgKO mice and disease outcome 
was tracked until the terminal stages of the disease. All 
mice within the wt group were euthanized by 30 days 
PGI due to ethical concerns, whereas two mice from the 
Nrp1MgKO group survived until day 50, at which point they 
were euthanized (Figure 2F). Nrp1MgKO mice displayed a 
significant increase in survival time based on a Mantel-
Cox log rank test (p = 0.0172, Figure 2F).
We then investigated whether pharmacologic 
inhibition of Nrp1 in wild-type mice with EG00229, 
which blocks the b1 domain of Nrp1, would have similar 
effects on tumor growth [26]. Pharmacokinetic evaluation 
of EG00229 in mice revealed a relatively short half-life of 
35 min (Supplementary Figure 2), suggesting that focal 
delivery via osmotic mini-pump would be the preferred 
route of delivery. We established that intraperitoneal 
administration of EG00229 at a concentration of 75 µM 
had no overt adverse effects in mice (data not shown) 
and used this concentration for loading the osmotic mini-
pumps. 
Gliomas were introduced in wt mice and EG00229 
delivered directly to the glioma injection site via a cannula 
connected to the pump for 15 or 20 days. Cannulas 
delivered the drug at a rate of 9.337µg dissolved in 0.25μL 
vehicle/hour to an estimated volume of distribution of 
approximately 20mm3, based off similar studies [36]. Due 
to these measurements, we estimated the drug’s resulting 
concentration in the tumor tissue to be approximately 
1 µM. We established that mice treated with saline had 
similar tumor burden to wt mice (Supplementary Figure 3). 
Gliomas were found to be significantly smaller and have 
decreased CD31+ vessel luminal area in mice administered 
EG00229 relative to those that developed in control wt 
mice (Figure 2A, 2D, 2E). To investigate whether delayed 
administration of the drug could still affect tumor volume, 
tumor development and vessel luminal area were assessed 
and found to still be significantly reduced at 15 days-post 
glioma induction (PGI) when EG00229 was administered 
8 days PGI (Figure 2D, 2E). No significant difference in 
tumor growth or vascularity was observed between tumors 
from Nrp1MgKO mice or EG00229-treated wt mice at any 
time point (Figure 2D, 2E). 
EG00229 binds specifically to Nrp1
The other Neuropilin isoform, Nrp2, is structurally 
similar to Nrp1 and has signaling roles in the CNS and 
other organ systems that partially overlap but are also 
distinct from those of Nrp1. To assess the selectivity of 
EG00229 towards Nrp1, isothermal calorimetry (ITC) was 
performed. EG00229 exhibited clear binding to a single 
site on Nrp1b1 domain with associated Kd of 0.2 μM, ΔH 
= -20640 µCal/mol and ΔS = -42.4 (µCal/mol)/K (Figure 
3A). In contrast, interaction between EG00229 and the 
Nrp2b1 domain was not detected (Figure 3B), indicating 
that EG00229 specifically interacts with Nrp1. 
Gliomas in mice with Nrp1-deficient microglia/
macrophages and mice treated with EG00229 
exhibit increased microglial/macrophage 
infiltration
Although pharmacologic inhibition of Nrp1 also 
targets tumor- and endothelial-Nrp1, genetic ablation of 
Nrp1 solely from microglia and macrophages decreased 
tumor volume and vascularity to the extent seen with the 
pharmacological treatment (Figure 2), suggesting that a 
critical role for Nrp1 in this setting is via signaling to/
from the GAMs. To investigate whether ablating Nrp1 
expression in GAMs alters their effect on the tumor or the 
tumor environment, tumor sections were immunostained 
using the microglia/macrophage marker, Iba1. Gliomas in 
wt mice were characterized by an Iba1+ cell density that 
was relatively uniform throughout the tumor (Figure 4A). 
In contrast, gliomas in Nrp1MgKO mice were encompassed 
by a dense layer of Iba1+ cells not observed in the wt 
mice (Figure 4A). Immunoblotting of crude tumor lysates 
yielded similar results: higher levels of the microglia/
macrophage marker F4/80 were present in Nrp1MgKO 
tumor lysates, accompanied by increased expression of 
TSPO, a marker of neuro-inflammation (Supplementary 
Figure 4). GAM density was similarly increased in the 
rims of tumors from Nrp1MgKO mice at 15 and 20 days of 
the disease course relative to GAM density in wt mice 
(Figure 4). Additionally, GAM density was found to be 
significantly elevated in the core of tumors in Nrp1MgKO 
mice although the difference was most profound at the 
rim (Supplementary Figure 4). GAM density within the 
tumor rims of EG00229-treated wt mice was, likewise, 
significantly elevated relative to the density of GAMs in 
the tumor rim in untreated wt mice (Figure 4B, 4C) and 
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Figure 3: Interaction of EG00229 with recombinant Nrp1b1 and Nrp2b1 domain measured by ITC. Representative 
experiment carried out by titrating EG00229 into A. Nrp1b1 and B. Nrp2b1. Titration data and integrated heat measurements are shown 
in the upper and lower plots, respectively. 
Figure 4: Nrp1 ablation or inhibition in microglia/macrophages increases their density within the glioma border. A. 
Representative images of Iba1+ microglia/macrophages (red) in gliomas (white dotted lines demarcate borders) in wt (top) and Nrp1MgKO 
mice (bottom) at 15 days PGI. B. Representative images of microglia/macrophage staining (Iba1, red) near the tumor border in wt mice, 
Nrp1MgKO mice, and wt mice treated with EG00229 for 15 days. Tumor cells are GFP+ (green). C. Quantification of the average density of 
Iba1+ microglia/macrophages within the tumor borders of wt mice, Nrp1MgKO mice, and mice treated with EG00229 for 15 days (D1-15), 
days 8-15 of the disease (D8-15), or 20 days (D1-20, **= p < 0.01, ***= p < 0.001, ****= p < 0.0001); WT D15, WT D20, KO D20: n = 
5; KO D15: n = 6, EGD1-15, EG D1-20: n = 3; EG D8-15: n = 4).
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similar to that observed in the Nrp1MgKO mice at 15 days 
PG1 but not quite as high at 20 days PGI (Figure 4C).
Nrp1-deficient microglia/macrophages and those 
in EG00229 treated mice exhibit increased anti-
tumorigenic polarization
Since macrophages are frequently polarized 
to a pro-tumorigenic phenotype that supports tumor 
vascularization and growth, we sought to understand 
how an increase in GAM density surrounding and in 
tumors of Nrp1MgKO and EG00229-treated wt mice could 
be inversely correlated with these outcomes. As Nrp1-
dependent pathways can play a role in the behavior of 
tumor-associated macrophages in the periphery, we 
examined the phenotypic state of the GAMs by assessing 
them for expression of CD86, CD206, and TSPO, which 
are markers of inflammatory status. Relative expression 
of these markers was quantified by calculating co-
localization between the markers and either F4/80 or Iba1 
as markers of the GAMs. The ratio of CD86 to CD206 is 
used as an indicator of the ratio of M1 (inflammatory, anti-
tumorigenic) polarization to M2 (pro-tumorigenic, anti-
inflammatory) polarization in populations of microglia and 
macrophages [37]. This ratio was significantly higher (i.e., 
shifted towards M1) in populations of GAMs populating 
tumor rims in Nrp1MgKO mice at days 15 and 20 days PGI 
relative to wt mice at the same time points (Figure 5). 
Additionally, the percentage of CD11b+ GAMs expressing 
high levels of CD86 and the ratio of GAMs expressing 
high levels of CD86 relative to those expressing high 
levels of CD206 were significantly higher in whole 
tumor extract of Nrp1MgKO mice (Figure 5). Expression of 
TSPO, a general marker for inflammatory activation, was 
significantly elevated in GAMs of Nrp1MgKO mice relative 
to those of wt mice at 15 days PGI (Supplementary Figure 
4). GAMs from tumors in wt mice treated with EG00229 
for variable amounts of time were similarly found to 
have an elevated ratio of CD86 to CD206 expression in 
comparison to GAMs populating tumors in untreated 
mice (Figure 5). Additionally, TSPO expression in GAMs 
was significantly higher in gliomas in mice treated with 
EG00229 relative to wt mice (Supplementary Figure 4). 
Figure 5: Nrp1 ablation or inhibition in microglia and macrophages alters their polarization in gliomas. A.-B. 
Representative images of CD86 (A) and CD206 (B) staining (white) in Iba1+ (red) microglia/macrophages in gliomas from wt mice, 
Nrp1MgKO mice, and wt mice treated with EG00229 for 15 days. C. CD11b+ cell populations isolated from whole tumor homogenate of 
wt and Nrp1MgKO mice (vertical axis: side scatter, bottom axis: forward scatter) D. Expression of CD86 and CD206 from CD11b-gated 
macrophages isolated from wt and Nrp1MgKO whole tumor homogenate. E. Quantification of co-localization ratio between CD86 and Iba1 
to the co-localization of CD206 and Iba1 in microglia/macrophages within the tumor borders of wt mice, Nrp1MgKO mice, and mice treated 
with EG00229 (*= p < 0.05, **= p < 0.01; WT D15, WT D20: n = 4; KO D15, KO D20, EGD1-15, EG D1-20: n = 3; EG D8-15: n = 5). 
F. Total percentage of CD11b+ cells which had high expression of CD86 in wt and Nrp1MgKO whole tumor homogenate and G. the ratios 
of CD86 high expressing cells to CD206 high expressing cells in wt and Nrp1MgKO whole tumor homogenate (*= p < 0.05, WT: n = 4, KO: 
n = 5).
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Nrp1 depletion or pharmacologic inhibition in 
microglia alters their association with glioma-
derived cells and increases their anti-tumorigenic 
polarization in the presence of glioma-derived 
cytokines
Since inhibition of Nrp1-dependent pathways has 
been reported to affect the growth of glioma-derived 
tumor cell lines [7, 20], we investigated the capacity 
of increasing amounts of EG00229 to suppress growth 
and migratory behavior of the GL261-eGFP cell line 
in vitro. Significant effects on cell survival (as assayed 
using propidium iodide (PI) staining) and migration 
were first seen at 12.5μM (Supplementary Figure 5). As 
we estimated steady state concentrations of EG00229 
administered to mice to be approximately 1μM, we do not 
expect that this was a significant factor affecting tumor 
growth in those mice. However, its contribution to the 
disease course cannot be ruled out based on our data.
Having noted differences in the polarity of wt 
and Nrp1MgKO GAMs in vivo, we investigated whether 
microglia and GL261-eGFP interact differently in vitro 
depending on the presence or absence of Nrp1 signaling by 
microglia. GL261-eGFP cells were plated onto basement 
membrane extract in the presence of wt or Nrp1MgKO 
microglia and they were grown together for 5 days (Figure 
6A). GL261eGFP cells assembled into spheres while 
nearby microglia were attracted into these spheres (Figure 
6B). Notably, as Nrp1MgKO microglia congregated around 
GL261-eGFP spheres, the fluorescence detected from 
the GL261-eGFP cells populating the spheres decreased. 
This was not observed when wt microglia migrated into 
GL261-eGFP spheres (Figure 6B), supporting the idea 
that Nrp1MgKO microglia associate differently with glioma-
derived cells. 
We previously established that GL261-conditioned 
media (GCM) alters microglial activity in vitro [29]. We 
examined whether Nrp1 deficiency affects the capacity 
of GCM to modify the microglial activation state. Wt 
Figure 6: Nrp1-deficient microglia exhibit a different pattern of association and polarization in the presence of 
glioma-derived cells and factors. A. Experimental setup for culturing primary microglia and GL261-eGFP cells in cultrex basement 
membrane extract. B. Representative images of microglia-GL261-eGFP associations over 5 days in cultrex basement membrane extract. 
C. Representative images of CD86 expression (green) by Iba1-stained wt and Nrp1MgKO microglia (red) pre-treated with DMSO/vehicle or 
12.5µM EG00229 (EG) for 12 hours, followed by exposure to glioma-conditioned media (GCM) for 12 hours. D. Quantification of CD86-
Iba1 co-localization in EG00229- and GCM-treated microglia (*= p < 0.05, **= p < 0.01, all groups: n = 3).
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or Nrp1MgKO microglia, pre-treated with EG00229 or 
DMSO vehicle, were cultured in the presence of GCM 
for 12 hours, and CD86 expression was evaluated by 
immunofluorescence. Wt microglia pre-treated with 
EG00229 showed a significant increase in the M1 marker, 
CD86, after GCM exposure, relative to those that were 
not exposed to GCM, whereas GCM-exposed wt microglia 
that were not pre-treated with EG00229 failed to show a 
significant increase in CD86 expression (Figure 6C, 6D). 
Consistent with this finding, CD86 expression increased 
with GCM treatment of Nrp1MgKO microglia whether or 
not they were pre-treated with EG00229 (Figure 6C, 6D).
Nrp1 depletion or pharmacologic inhibition in 
microglia impairs the activation of the SMAD2/3 
pathway
To address why Nrp1-deficient and EG00229-treated 
wt microglia showed differences in M1 polarization in the 
presence of glioma-derived mediators, we investigated 
whether they exhibited deficits in signaling via Nrp1-
dependent pathways related to polarization. Since 
Nrp1 is a co-receptor for TGFβ, and having previously 
demonstrated that microglia show increased activation of 
the M2-associated SMAD2/3 pathway in the presence of 
the Nrp1 agonist, tuftsin [25], we investigated whether the 
activity of this pathway differed between wt and Nrp1MgKO 
microglia in the presence of GCM. We assessed basal 
activation of SMAD2/3 in wt and Nrp1MgKO microglia: 
no appreciable difference in SMAD2/3 expression or its 
activation was evident between the two cell populations 
(Supplementary Figure 4). Wt microglia were incubated 
with or without EG00229 and stimulated with GCM for 
30 minutes. Nrp1MgKO microglia were also stimulated with 
GCM for 30 minutes and SMAD2/3 activation assessed 
by immunoblotting for the ratio of phosphorylated 
SMAD2/3 to total SMAD2/3. Wt microglia treated 
with GCM showed significantly increased SMAD2/3 
activation relative to the wt control, whereas the Nrp1MgKO 
microglia did not (Figure 7A, 7B). Similarly, wt microglia 
pre-treated with EG00229 did not show activation of 
SMAD2/3 after treatment with GCM (Figure 7C, 7D).
DISCUSSION
Our results demonstrate that Nrp1 signaling in 
GAMs plays a key role in their interaction with the glioma 
Figure 7: Nrp1 ablation or inhibition blocks SMAD2/3 activation in glioma-conditioned media. A. Representative blots 
of pSMAD2/3 and SMAD2/3 expression by wt and Nrp1MgKO microglia after stimulation with GL261-conditioned media (GCM). B. 
Quantification of SMAD2/3 phosphorylation relative to total SMAD2/3. expression in wt and Nrp1MgKO microglia. GCM-treated samples 
were standardized to untreated samples (*= p < 0.05). C.-D. Representative blot (C) and quantification (D) of pSMAD2/3 to total SMAD2/3 
levels in microglia pre-treated with EG00229 and then either treated with DMEM + 10% FBS (WT+EG) or GCM (WT+EG+GCM). GCM-
treated samples were standardized to untreated samples (WT, WT+GCM: n = 5, KO, KO+GCM: n = 4, WT+EG, WT+EG+GCM: n = 5).
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microenvironment, promoting their polarization to a pro-
tumorigenic phenotype and thereby facilitating tumor 
growth and neovascularization. We present evidence 
that ablation of Nrp1 in GAMs or focal treatment with 
EG00229, an inhibitor of Nrp1’s b1 domain, modulates 
the way GAMs interact with glioma-derived tumor cells 
and tumor-cell generated cytokines, resulting in alterations 
in their polarization which correlate with slower disease 
progression.
Nrp1 is also expressed by other cell types, raising 
the question of whether the ability of EG00229 to suppress 
tumor growth is also due to its effects on endothelial 
cells [26] and/or the glioma tumor cells. The EG00229 
concentrations used in vivo were not high enough to be 
cytotoxic to tumor cells, but other effects on cells within 
the tumor microenvironment cannot be ruled out in 
contributing to a slower disease course. 
The related receptor Nrp2 is also expressed on 
microglia. As we presented here, ITC binding using 
recombinant Nrp1b1 and Nrp2b1 domains demonstrated 
that EG00229 was fully selective for Nrp1b1, suggesting 
that it is only necessary to inhibit Nrp1 to achieve anti-
tumoral immunity, again decreasing the potential for 
toxicity at the doses required for therapeutic effect. New 
and more potent EG00229 analogues are being explored 
that will improve its utilization in the clinical setting.
Our results demonstrate that Nrp1 ablation from 
GAMs or pharmacologic inhibition of Nrp1 signaling 
causes anti-tumorigenic GAMs to infiltrate and 
accumulate at the actively expanding glioma border. This 
is correlated with a reduction in overall tumor vascularity 
and growth. While it is possible that some macrophages 
did not undergo cre-recombinase induced excision of the 
Nrp1 gene, a large population of Nrp1-depleted-, CSF1R-
expressing cells was apparent in tumors of Nrp1MgKO mice 
(Figure 2). Our finding that macrophage density within 
tumors increases when Nrp1 is knocked out is similar 
to the report of Casazza and colleagues who observed 
increased infiltration of squamous cell carcinoma tumors 
by macrophages in mice with Nrp1 depletion of Ly6C 
expressing myeloid cells [8].
GAMs near the invasive edge of gliomas in humans 
and mice upregulate expression of TGF-β, which in turn 
increases glioma invasiveness [38]. Nrp1 functions as 
co-receptor for TGFβ that amplifies SMAD2/3 signaling 
in GAMs, which promotes M2 polarization of microglia 
[19, 25]. We show here that Nrp1MgKO microglia fail to 
activate SMAD2/3 signaling in response to glioma tumor 
cell-conditioned media that contains TGFβ in addition 
to other cytokines, and that this altered combination of 
signaling pathways underlies their increased M1, anti-
tumoral polarization. It should be noted that other Nrp1-
mediated pathways, particularly VEGFA, semaphorin 3A, 
and HGF signaling may also play important roles in the 
overall modalities of how GAMs associate with the tumor 
microenvironment. Furthermore, it would be worthwhile 
to analyze transcriptional differences between wild type 
and Nrp1MgKO GAMs isolated from tumors to assess 
significant alterations in gene expression in an unbiased 
manner.
GL261 tumors have been shown to recapitulate 
many characteristics of GBM [39]. Evaluation of tumors 
reveals histologic pleomorphism, pseudopalisades around 
necrotic areas, and tumoral neoangiogenesis. GL261 
tumors are invasive, but not metastatic. Moreover they 
present moderate immunogenicity. Validation of our 
results with additional astrocytoma cell lines of both 
murine and human origin would be important, although 
to study this pathway with human-derived glioma cell 
lines, immunocompromised animals are required, which 
presents a significant drawback in the study of anti-
tumoral immunity. Additionally, it would be critical 
to analyze more glioma biopsies to firmly establish a 
correlation of Nrp1 expression in macrophages with the 
severity of the disease course.
Our results are the first to our knowledge to 
demonstrate that in vivo pharmacological inhibition 
of Nrp1, not just its genetic ablation, results in better 
outcomes in the glioma disease course. Taken together, 
these findings support the investigation of Nrp1-selective 
inhibitors as potential therapeutics for gliomas.
MATERIALS AND METHODS
Evaluation of human tumors
Four patients with primary glioma who had 
undergone surgical resection from 2000 to 2013 at the 
Stony Brook University Medical Center (Stony Brook, 
NY) were selected based on the availability of sufficient 
remnant tissue to support the aims of this study. Patient 
clinical information was provided by the Cancer Registry 
of Stony Brook University Medical Center, including data 
about patient age, sex, treatment, tumor recurrence, and 
survival. Use of archival surgical pathology specimens for 
immunohistochemical studies (Committees on Research 
Involving Human Subjects protocol 94651) was approved 
by the Institution Review Board of Stony Brook University 
Medical Center. Representative tissue blocks from each 
case were assembled from the archival collections from 
Department of Pathology and were graded according to 
World Health Organization standards, as pilocytic (grade 
I), grade II, grade III, and grade IV tumors.
Five-micrometer, formalin-fixed, paraffin-
embedded tissue sections were deparaffinized in xylenes 
and rehydrated in graded alcohols. Antigen retrieval was 
performed in citrate buffer (20 mmol/L, pH 6.0) at 100°C 
for 20 min. The slides were allowed to dry, after which 
they were subjected to three PBS washes. Non-specific 
protein interactions were blocked by pretreatment with 
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5% goat serum in 0.1% Tween-20-supplement PBS for 1 
hour and immunolocalization was performed using anti-
human Nrp1 (1:50) (Santa Cruz Technologies) and Iba1 
(1:1000) (Wako) primary antibodies. The slides were 
next washed thrice with PBS, stained with alexa-fluor 
conjugated secondary antibodies for 2 hours at room 
temperature, washed with PBS, and cover-slipped with 
DAPI fluoromount. Co-localization of Nrp1 and iba1 was 
assessed by confocal microscopy.
Glioma-derived cell line
The GL261 cell line (available through the Division 
of Cancer Treatment and Diagnosis Tumor Repository 
at the National Cancer Institute) is derived from a 
chemically-induced C57BL/6 murine astroglioma [28]. 
We previously stably transfected the cells with an eGFP 
construct, generating the cell line, GL261-eGFP, which 
has been characterized in culture and in an in vivo glioma 
model [29]. This cell line was expanded in Dulbecco’s 
Modified Eagle Media (DMEM) supplemented with 
10% heat-inactivated Fetal Bovine Serum (FBS) and 1x 
Penicillin/Streptomycin (P/S).
Animals
Mice were bred under maximum isolation 
conditions on a 12:12 hour light: dark cycle with food 
ad libitum. Littermates from Nrp1fl/fl x Nrp1fl/fl Csf1R-cre 
breeding pairs were used for experiments [30, 31]. Mice 
expressing cre recombinase (Nrp1MgKO) effectively lack 
Nrp1 in microglia and macrophages. Littermates lacking 
cre recombinase are considered ‘wild-type’. All mice were 
bred on the C57BL/6 background. 
Genotyping
Tissue was acquired from mice by tail snip. Crude 
DNA was extracted by boiling the tissue in 50mM NaOH 
for 10 minutes followed by pH neutralization via the 
addition of 1M Tris-HCl (pH 8.0). Presence of Csf1R-
cre and/or the floxed Nrp1 alleles was confirmed using 
Crimson Taq PCR (New England Biotechnologies) with 
primers designed against their appropriate gene sequences 
(See Supplementary Table 1). All mice were genotyped 
prior to use.
Primary microglia
Primary microglia were harvested as previously 
described [32]. Briefly, 0-3 day old (d0-3) mice were 
decapitated and their cerebral cortices were dissected in 
ice-cold 1x Hank’s Buffered Salt Solution (1x HBSS, 
Thermo Fisher Scientific Inc.). The cortices were 
trypsinized, homogenized, and plated in DMEM (Thermo 
Fisher Scientific Inc.) supplemented with 10% FBS, and 1x 
P/S. Media was replaced on the 3rd day. After 10-15 days, 
the cultures were treated with lidocaine (Sigma), gently 
rocked, and microglia were isolated from the supernatant, 
counted, and resuspended in DMEM supplemented with 
1%FBS and 1x P/S. For live imaging of microglia, 20μg/
mL Mini-Ruby (Invitrogen) was added to media for 24 
hours, after which the media was removed, the culture 
was rinsed in 1x HBSS, and media was replaced [33]. All 
microglia were used for experiments within 48 hours of 
plating. 
Evaluation of EG00229 cytotoxicity
For evaluation of EG00229-induced cell death, 
10,000 GL261-eGFP cells were plated per well in a 96-
well plate and incubated in different concentrations of 
EG00229 for 24 hours. GL261-eGFP cells were then 
washed in HBSS, incubated with 1µg/mL propidium 
iodide for 10 minutes, washed, and fixed in 4%w/v PFA. 
63x images were taken in six random fields of view and 
PI+-stained cells were counted to determine drug-induced 
cell death.
Transwell migration assays
GL261-eGFP cells were serum starved for 24 hours 
then harvested, counted, washed, and resuspended in 
serum-free DMEM. 10,000 GL261-eGFP cells were plated 
to 8.0µm transwell inserts (Corning) suspended over 
DMEM supplemented with 10%FBS containing different 
concentrations of the Nrp1 inhibitor EG00229. Transwell 
cultures were allowed to grow for 24 hours after which 
non-migratory cells were gently scraped from the top of 
the transwell membranes using cotton Q-tips. Membranes 
were then fixed in 4%PFA, washed in 1x PBS, stained 
with DAPI, and cell migration across the membranes 
evaluated by counting the number of nuclei within five 
random 20x fields for each transwell insert. 
RNA extraction
RNA was harvested from cells by first removing 
their media, washing them with PBS, and lysing them 
with RNA-Bee (Tel-Test) according to the manufacturer’s 
protocol. To obtain cDNA, one microgram of RNA was 
reverse transcribed on a Veriti Thermocycler (Applied 
Biosystems) using the High Capacity cDNA Reverse 
Transcription kit. Amplification of cDNA products was 
performed using primers against RNA products of interest 
using a Veriti Thermocycler (see Supplementary Table 1). 
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Murine glioma model
Gliomas were established in 3-4 month old mice as 
previously described [29]. Briefly, mice were anesthetized 
using atropine (0.6 mg/kg, i.p.) and 2.5% avertin (0.02 
mg/g, i.p.). A midline incision was made on the scalp and 
a small burr hole was drilled in the skull at stereotactic 
coordinates of bregma, −1 mm anteroposterior and +2 
mm mediolateral. 3 x 104 GL261-eGFP cells suspended 
in 1μL of PBS were injected in anesthetized mice over 
two minutes at a depth of 3mm. Local delivery of 
drugs to the gliomas was achieved using mini-osmotic 
pumps (Alzet) connected via rubber tubing to 3mm 
cannulas (PlasticsOne) positioned directly over the 
injection tracks. Pumps were either filled with saline 
+ 0.75%DMSO vehicle or 75μM EG00229 (in 0.75% 
DMSO) and subcutaneously implanted into the backs 
of mice, as previously described [29]. After completion 
of the procedure, the incision was sutured and the mice 
were placed on a heated surface until fully recovered 
from anesthesia. Buprenorphine was administered to mice 
for pain management if signs of distress were observed. 
If mice were found to have lost more than 30% of their 
initial body weight over the disease course, they were 
euthanized. All animal procedures were approved by the 
Stony Brook University Institutional Animal Care and Use 
Committee (IACUC).
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments 
were carried out in a reaction buffer (20 mM Tris pH 
7.9, 50 mM NaCl) using a VP-ITC titration calorimeter 
(MicroCal, LLC) with a reaction cell volume of 1.4 mL at 
15 °C. Recombinant Nrp1b1 and Nrp2b1 were prepared 
as previously described [26]. Prior to the experiments, 
Nrp1b1 and Nrp2b1 samples were each dialyzed in the 
same buffer and all solutions, including the buffer that was 
used for heat dilution measurements, and were degassed 
and filtered just before loading into the calorimeter. 
5 μM Nrp2b1 or 5 µM Nrp1b1 in the reaction cell was 
titrated with the 50 μM stock solutions of EG00229. 19 
consecutive compound injections of 15 μL at 2 second/
μL were applied at 4 minutes intervals, while stirring the 
reaction solution at 300 rpm constant speed. For heat 
dilution of the protein, 1.4 mL of reaction buffer in the 
reaction cell was titrated by 300 μL of 50 µM compound 
and this value was subtracted from the measured heats 
of binding. Protein concentrations of the samples used 
in these experiments were estimated by UV absorbance 
measurements at 280nm.
Imaging
Image acquisition was performed on either a Nikon 
Eclipse E600 Microscope (Nikon) or a Zeiss LSM 510 
confocal microscope (Zeiss). 
Immunohistochemistry
For evaluation of tumor tissue at different time 
points, mice were deeply anesthetized with 2.5% avertin 
and transcardially perfused with 50 mL PBS followed by 
50 mL 4% paraformaldehyde (PFA) in PBS. Brain tissue 
was removed and post-fixed in 4% PFA/PBS for 12 hours 
followed by 30%w/v sucrose in PBS at 4°C until fully 
dehydrated. The brains were then embedded in optimal 
cutting temperature compound (Tissue-Tek), and sectioned 
using a Leica cryostat (Nussloch, Germany). 20-μm thick 
coronal sections of throughout all tumor containing tissue 
were taken for analysis.
For evaluation of tumor volumes, serial sections 
were evaluated through the largest portions of tumor and 
tumor diameters were measured and averaged to calculate 
an average tumor radius using NIS-Elements software 
(Nikon Instruments Inc.) As GL261-based tumors grow 
spherically, volume was calculated using the equation V 
= 4/3πr3.
For evaluation of tumor vascularity, serial sections 
were stained with anti-CD-31 (1:500) (Millipore). 
Photomicrographs, including 10 random 40x images 
within tumors were captured and tumor vascularity for 
each specimen calculated by summating the total luminal 
area bounded by CD31+ staining for blood vessels using 
NIS-elements software (Nikon Instruments Inc.).
For evaluation of intra-tumoral inflammation, 
sections were stained for either F4/80 (1:500) (Abcam) or 
iba1 (1:1000) (Wako) to evaluate GAM populations. Areas 
surrounding the needle tract from the tumor cell injection 
were excluded from imaging analysis. Random, 63x fields 
of view within the center of tumors or within the border of 
tumors were used to evaluate GAM density. Co-staining 
with iba1 or F4/80 and CD86 (1:50) (Millipore), 1:50 
CD206 (R&D Systems Inc.), and 1:500 TSPO (Abcam) 
was used to evaluate GAM polarization. Additionally, 
sections were stained with 1:100 Csf1R (VWR) and 
1:100 Nrp1 (R&D Biosystems) antibodies. random, 63x 
images were taken for each section and Image J (NIH) 
used to calculate Mander’s co-localization coefficient 
between iba1 or F4/80 and each inflammation marker. 
Ratios of average CD86 to CD206 co-localization were 




Cells or tissue were lysed on ice in 50 mM Tris-
HCl (pH 7.4) containing 1% Nonidet P-40, 0.25% Na 
deoxycholate, 150 mM NaCl, 1% SDS, and 1x protease 
inhibitor cocktail (Sigma-Aldrich). Debris was spun 
out of samples at 14,000rpm and tissue supernatant was 
resuspended and denatured by boiling and treatment with 
β-mercaptoethanol, run using SDS-PAGE, and transferred 
to PVDF membranes (Immobilon; Millipore). Membranes 
were then washed in Tris-buffered saline containing 0.05% 
tween-20 (pH 7.40, TBS-T), blocked in 5% BSA or 5% 
skim milk powder for 1 hour and probed using p-Smad2/3 
(Cell Signaling, 1:1000), Smad2/3 (Cell Signaling, 
1:1000), F4/80 (Abcam, 1:500), Csf1R (VWR, 1:200), 
Iba1 (WAKO, 1:1000), α-actin (Santa Cruz, 1:5000) or 
TSPO (Abcam, 1:500) overnight. Membranes were then 
rinsed in TBS-T, probed with appropriate HRP-conjugated 
secondary antibodies, rinsed in TBS-T, and exposed to 
Pierce ECL substrate (Thermo Fisher Scientific Inc.) for 
1 minute after which X-ray films (Denville Scientific 
Inc.) were developed from the membranes. Densitometry 
analysis was performed using Image J (NIH). Antibodies 
were stripped from membranes in 0.1% SDS, 1% 
Tween-20, 1.5% glycine, pH 2.2 stripping buffer (Abcam) 
via two 10-minute incubations at room temperature.
Flow cytometry
Mice were heavily anesthetized with avertin and 
transcardially perfused with 50mL ice cold PBS. Mouse 
brains were extracted and tumor tissue was micro-dissected 
and placed in ice cold FACS buffer (pH 7.40, 0.1M PBS, 
1mM EDTA, 1% BSA, 50U/mL DNase I). Tissue was then 
subjected to digestion in papain supplemented with 50U/
mL DNase I for 30 minutes followed by gentle trituration. 
Tissue homogenates were passed through 40μM filters and 
resuspended in 30% Percoll in 1x HBSS. Samples were 
spun for 15 minutes at 1500rpm after which the pelleted 
fractions were resuspended in FACS buffer. Samples were 
washed and stained with CD11B-APC, CD86-PE, and 
CD206-Pacific Blue antibodies for 1 hour (all at 1:100, 
Biolegend). Samples were then washed in FACS buffer 
thrice, fixed in 1%PFA w/v and cell staining was analyzed 
on a BD FACS Calibur using BD FACSDiva software (BD 
Biosciences).
Statistical analysis
Data comparing two population means were 
analyzed using Student’s T-tests. Data assessing 
differences between multiple population means were 
compared by one-way ANOVA with Tukey’s post-hoc test 
analysis. A p-value < 0.05 was accepted as designating 
significant difference between two population means 
with 95% confidence. Differences in survival between 
populations were analyzed by the Mantel-Cox log rank 
test. Statistical analysis was performed using Graphpad 
Prism (Graphpad Software Inc., La Jolla, CA).
ACKNOWLEDGMENTS
We thank members of the Tsirka lab and Dr. Michael 
Frohman for helpful advice and discussions. We also thank 
Stephanie Burke who helped with the immunofluorescence 








1. Omuro A and DeAngelis LM. Glioblastoma and other 
malignant gliomas: a clinical review. JAMA. 2013; 
310:1842-50.
2. Wen PY and Kesari S. Malignant gliomas in adults. N Engl 
J Med. 2008; 359:492-507.
3. da Fonseca AC and Badie B. Microglia and macrophages 
in malignant gliomas: recent discoveries and implications 
for promising therapies. Clin Dev Immunol. 2013; 
2013:264124.
4. Osada H, Tokunaga T, Nishi M, Hatanaka H, Abe Y, Tsugu 
A, Kijima H, Yamazaki H, Ueyama Y, and Nakamura M. 
Overexpression of the neuropilin 1 (NRP1) gene correlated 
with poor prognosis in human glioma. Anticancer Res. 
2004; 24:547-52.
5. Evans I, Yamaji M, Britton G, Pellet-Many C, Lockie C, 
Zachary I, and Frankel P. Neuropilin-1 signaling through 
p130Cas tyrosine phosphorylation is essential for growth 
factor-dependent migration of glioma and endothelial cells. 
Mol Cell Biol. 2011; 31:1174-85.
6. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, 
Lee M, Moudry P, Bartek Jr J, Fischer W, Lukas J, Rich 
JN, and Bartek J. Autocrine VEGF-VEGFR2-Neuropilin-1 
signaling promotes glioma stem-like cell viability and 
tumor growth. J Exp Med. 2012; 209:507-20.
7. Nasarre C, Roth M, Jacob L, Roth L, Koncina E, Thien 
A, Labourdette G, Poulet P, Hubert P, Cremel G, Roussel 
G, Aunis D, and Bagnard D. Peptide-based interference of 
the transmembrane domain of neuropilin-1 inhibits glioma 
growth in vivo. Oncogene. 2010; 29:2381-92.
Oncotarget9813www.impactjournals.com/oncotarget
8. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, 
Mambretti M, Deschoemaeker S, Van Ginderachter JA, 
Tamagnone L, and Mazzone M. Impeding macrophage 
entry into hypoxic tumor areas by Sema3A/Nrp1 signaling 
blockade inhibits angiogenesis and restores antitumor 
immunity. Cancer Cell. 2013; 24:695-709.
9. Graeber MB, Scheithauer BW, and Kreutzberg GW. 
Microglia in brain tumors. Glia. 2002; 40:252-9.
10. Wei J, Gabrusiewicz K, and Heimberger A. The 
controversial role of microglia in malignant gliomas. Clin 
Dev Immunol. 2013; 2013:285246.
11. Biswas SK and Mantovani A. Macrophage plasticity and 
interaction with lymphocyte subsets: cancer as a paradigm. 
Nat Immunol. 2010; 11:889-96.
12. Sarkar S, Doring A, Zemp FJ, Silva C, Lun X, Wang X, 
Kelly J, Hader W, Hamilton M, Mercier P,  Dunn JF, 
Kinniburgh D, van Rooijen N, et al. Therapeutic activation 
of macrophages and microglia to suppress brain tumor-
initiating cells. Nat Neurosci. 2014; 17:46-55.
13. Golestaneh N and Mishra B. TGF-beta, neuronal stem cells 
and glioblastoma. Oncogene. 2005; 24:5722-30.
14. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, and 
Mentlein R. Expression of VEGF and its receptors in 
different brain tumors. Neurol Res. 2005; 27:371-7.
15. Kunkel P, Muller S, Schirmacher P, Stavrou D, Fillbrandt 
R, Westphal M, and Lamszus K. Expression and 
localization of scatter factor/hepatocyte growth factor in 
human astrocytomas. Neuro Oncol. 2001; 3:82-8.
16. Bagci T, Wu JK, Pfannl R, Ilag LL, and Jay DG. Autocrine 
semaphorin 3A signaling promotes glioblastoma dispersal. 
Oncogene. 2009; 28:3537-50.
17. Prud’homme GJ and Glinka Y, Neuropilins are 
multifunctional coreceptors involved in tumor initiation, 
growth, metastasis and immunity. Oncotarget. 2012; 3:921-
39. doi: 10.18632/oncotarget.626.
18. Glinka Y and Prud’homme GJ. Neuropilin-1 is a receptor 
for transforming growth factor beta-1, activates its latent 
form, and promotes regulatory T cell activity. J Leukoc 
Biol. 2008; 84:302-10.
19. Moransard M, Sawitzky M, Fontana A, and Suter T. 
Expression of the HGF receptor c-met by macrophages in 
experimental autoimmune encephalomyelitis. Glia. 2010; 
58:559-71.
20. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, 
Bogler O, Mikkelsen T, Hirose T, Nishikawa R, and Cheng 
SY. Neuropilin-1 promotes human glioma progression 
through potentiating the activity of the HGF/SF autocrine 
pathway. Oncogene. 2007; 26:5577-86.
21. Raimondi C, Fantin A, Lampropoulou A, Denti L, Chikh 
A, and Ruhrberg C, Imatinib inhibits VEGF-independent 
angiogenesis by targeting neuropilin 1-dependent ABL1 
activation in endothelial cells. J Exp Med. 2014; 211:1167-
83.
22. Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, and Yong 
VW. A dialog between glioma and microglia that promotes 
tumor invasiveness through the CCL2/CCR2/interleukin-6 
axis. Carcinogenesis. 2012; 33:312-9.
23. Di Renzo MF, Bertolotto A, Olivero M, Putzolu P, Crepaldi 
T, Schiffer D, Pagni CA, and Comoglio PM. Selective 
expression of the Met/HGF receptor in human central 
nervous system microglia. Oncogene. 1993; 8:219-22.
24. Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, 
Langmann T, Holtman IR, Wang X, Eggen BJ, Boddeke 
HW, Hambardzumyan D, Wolf SA, and Kettenmann H. 
Glioma-associated microglia/macrophages display an 
expression profile different from m1 and m2 polarization 
and highly express gpnmb and spp1. PLoS One. 2015; 10: 
e0116644.
25. Nissen JC, Selwood DL, and Tsirka SE. Tuftsin signals 
through its receptor neuropilin-1 via the transforming 
growth factor beta pathway. J Neurochem. 2013; 127:394-
402.
26. Jarvis, A, Allerston CK, Jia H, Herzog B, Garza-Garcia 
A, Winfield N, Ellard K, Aqil R, Lynch R,  Chapman C, 
Hartzoulakis B, Nally J, Stewart M, et al. Small molecule 
inhibitors of the neuropilin-1 vascular endothelial growth 
factor A (VEGF-A) interaction. J Med Chem. 2010; 
53:2215-26.
27. Glinka, Y, Stoilova S, Mohammed N, and Prud’homme GJ. 
Neuropilin-1 exerts co-receptor function for TGF-beta-1 
on the membrane of cancer cells and enhances responses 
to both latent and active TGF-beta. Carcinogenesis. 2011; 
32:613-21.
28. Ausman JI, Shapiro WR, and Rall DP. Studies on the 
chemotherapy of experimental brain tumors: development 
of an experimental model. Cancer Res. 1970; 30:2394-400.
29. Zhai H, Heppner FL, and Tsirka SE, Microglia/macrophages 
promote glioma progression. Glia. 2011; 59:472-85.
30. Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y, 
Orlofsky A, Liu Q, Hume DA, Pollard JW, Augenlicht L, 
and Lin EY. A novel mouse model of inflammatory bowel 
disease links mammalian target of rapamycin-dependent 
hyperproliferation of colonic epithelium to inflammation-
associated tumorigenesis. Am J Pathol. 2010; 176:952-67.
31. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, 
Richards LJ, Kolodkin AL, and Ginty DD. Neuropilin-1 
conveys semaphorin and VEGF signaling during neural and 
cardiovascular development. Dev Cell. 2003; 5:45-57.
32. Rogove AD and Tsirka SE. Neurotoxic responses by 
microglia elicited by excitotoxic injury in the mouse 
hippocampus. Curr Biol. 1998; 8:19-25.
33. Ji K, Akgul G, Wollmuth LP, and Tsirka SE. Microglia 
actively regulate the number of functional synapses. PLoS 
One. 2013; 8:e56293.
34. Charles NA, Holland EC, Gilbertson R, Glass R, and 
Kettenmann H. The brain tumor microenvironment. Glia. 
2011; 59:1169-80.
35. Szatmari T, Lumniczky K, Desaknai S, Trajcevski 
Oncotarget9814www.impactjournals.com/oncotarget
S, Hidvegi EJ, Hamada H, and Safrany G. Detailed 
characterization of the mouse glioma 261 tumor model 
for experimental glioblastoma therapy. Cancer Sci. 2006; 
97:546-53.
36. Kawakami K, Kawakami M, Kioi M, Husain SR, and Puri 
RK. Distribution kinetics of targeted cytotoxin in glioma by 
bolus or convection-enhanced delivery in a murine model. J 
Neurosurg. 2004; 101:1004-11.
37. Walker PA, Bedi SS, Shah SK, Jimenez F, Xue H, Hamilton 
JA, Smith P, Thomas CP, Mays RW, Pati S, and Cox Jr CS. 
Intravenous multipotent adult progenitor cell therapy after 
traumatic brain injury: modulation of the resident microglia 
population. J Neuroinflammation. 2012; 9:228.
38. Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L, Xiao 
HL, Wang B, Yi L, Wang QL, Jiang XF, Yang L, Zhang P, 
et al. Tumor-associated microglia/macrophages enhance the 
invasion of glioma stem-like cells via TGF-beta1 signaling 
pathway. J Immunol. 2012; 189:444-53.
39. Oh T, Fakurnejad S, Sayegh ET, Clark AJ, Ivan ME, 
Sun MZ, Safaee M, Bloch O, James CD, and Parsa 
AT. Immunocompetent murine models for the study of 
glioblastoma immunotherapy. J Transl Med. 2014; 12:107..
